The role of selective oestrogen receptor modulators in the treatment of endometrial bleeding in women using long-acting progestin contraception

Human Reproduction

Volumn 15, Issue , 2000, Pages 30-38

  Grow, D R ^a   Reece, M T ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endometrial bleeding; Mifepristone; Progestin only contraception; Selective oestrogen receptor modulators

Indexed keywords

11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CLOMIFENE CITRATE; DESOGESTREL; ESTRADIOL; ESTRONE SULFATE; ETHINYLESTRADIOL; FOLLITROPIN; GESTAGEN; GONADORELIN AGONIST; IBUPROFEN; LEVONORGESTREL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; ONAPRISTONE; PLASMINOGEN ACTIVATOR; RALOXIFENE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TAMOXIFEN;

AMENORRHEA; ANGIOGENESIS; BREAKTHROUGH BLEEDING; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; EXPERIMENTAL MODEL; FEMALE; HORMONAL CONTRACEPTION; HUMAN; INFERTILITY; MONKEY; NONHUMAN; OSTEOPOROSIS; OVARY CYST; PATIENT SATISFACTION; POSTMENOPAUSE; VAGINA BLEEDING; VARICOSIS;

EID: 0033832053     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.suppl_3.30     Document Type: Article

References (40)

1. Endometrial blood flow response to oestrogen replacement therapy and tamoxifen in asymptomatic, postmenopausal women: A transvaginal doppler study
2. Hormonal treatments for bleeding abnormalities in Norplant users
3. Reproductive endocrine and endometrial effect of raloxifene hydrochloride, a selective oestrogen receptor modulator in women with regular menstrual cycles
4. The analysis of vaginal bleeding patterns induced by fertility regulating methods
5. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
6. The effect of transdermal estradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users
7. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines
8. Oestrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens
9. Effects of raloxifene in bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
10. Clinical assessment of treatment of prolonged bleeding in users of Norplant implants
11. Inhibition of angiogenesis by antioestrogens
12. Endometrial endothelial cell proliferation in long-term users of subdermal levonorgestrel
13. Structural characterization and biological functions of fibroblast growth factor
14. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: A 1-year primate study
15. Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: A 1-year primate study on contraception and amenorrhea
16. Endometrial thickness in tamoxifen-treated patients: Correlation with clinical and pathologic findings
17. Signaling vascular morphogenesis and maintenance
18. Endometrial vasculature in Norplant users: Preliminary results from a hysteroscopic study
19. Sex steroids and growth factors differentially regulate the growth and differentiation of cultured human endometrial stromal cells
20. Effects of tamoxifen uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial
21. EM-652 (SCH 567068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
22. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen
23. Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis
24. RU486 exerts antioestrogenic activities through a novel progesterone receptor A form-mediated mechanism
25. Pharmacokinetics of depomedroxyprogesterone acetate contraception
26. Morphological action of tamoxifen in the endometrium of persistent estrous rats
27. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
28. Sex steroids modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: Implications for the neovascularization of normal and neoplastic endometrium
29. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel
30. Endometrial vasculature in Norplant users
31. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception
32. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depomedroxyprogesterone acetate for contraception
33. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg: II. The comparison of bleeding patterns
34. Raloxifene, tamoxifen, nafoxidine, or oestrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
35. Ovarian cyst formation in two premenopausal patients treated with tamoxifen for breast cancer
36. Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer
37. Angiogenic growth factor expression in the uterus
38. Continuation rates among injectable contraceptive users
39. Once monthly antiprogestin controls menstrual bleeding during progestin-only contraception in primates
40. Identification of an oestrogen response element activated by metabolites of 17β-estradiol and raloxifene